Abstract: Rain streaks in outdoor images can severely affect the performance of high-level vision tasks, such as surveillance and autonomous driving, by obscuring important image details. The ...

Analysis suggests consumption at Northumberland site could be 50 times higher than US operator QTS estimates The UK’s largest proposed datacentre is understating the scale of its planned water use, ...

Abstract: Dear Editor, This letter proposes a fuzzy indirect iterative learning (FIIL) active disturbance rejection control (ADRC) scheme to address the impact of uncertain factors of plant-protection ...

The following slide deck was published by Recursion Pharmaceuticals, Inc. in conjunction with this event.

Google on Monday announced a set of new security features in Chrome, following the company's addition of agentic artificial intelligence (AI) capabilities to the web browser. To that end, the tech ...

Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our ...

Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock rose 7% Monday following positive Phase 2 trial results for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), a ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...